Trends in medicaid reimbursements for insulin from 1991 through 2014

JAMA Internal Medicine

Volumn 175, Issue 10, 2015, Pages 1681-1686

  Luo, Jing ^a   Avorn, Jerry ^a   Kesselheim, Aaron S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; GENERIC DRUG; INSULIN;

ARTICLE; COMPETITION; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; HEALTH CARE POLICY; HUMAN; MEDICAID; MEDICARE; PHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES; CLASSIFICATION; COST; ECONOMICS; STATISTICS AND NUMERICAL DATA; TRENDS;

COSTS AND COST ANALYSIS; DIABETES MELLITUS; DRUG COSTS; DRUGS, GENERIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSURANCE, HEALTH, REIMBURSEMENT; MEDICAID; UNITED STATES;

EID: 84943563726     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.4338     Document Type: Article

References (38)

1. Strachan MW, Frier BM. Insulin Therapy: A Pocket Guide. Springer; 2013.
2. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12(3): 141-146.
3. Forsham PH. Milestones in the 60-year history of insulin (1922-1982). Diabetes Care. 1982;5(suppl 2):1-3.
4. Hirsch IB. Insulin analogues. N Engl J Med. 2005; 352(2):174-183.
5. Greene JA, Riggs KR. Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med. 2015;372(12):1171-1175.
6. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007; 29(6, pt 1):1294-1305.
7. Hall JA, Summers KH, Obenchain RL. Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. J Manag Care Pharm. 2003;9(3):263-268.
8. Holleman F, Gale EA. Nice insulins, pity about the evidence. Diabetologia. 2007;50(9): 1783-1790.
9. Miller DR, Gardner JA, Hendricks AM, Zhang Q, Fincke BG. Health care resource utilization and expenditures associated with the use of insulin glargine. Clin Ther. 2007;29(3):478-487.
10. Gale EA. Newer insulins in type 2 diabetes. BMJ. 2012;345:e4611.
11. Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007∗. Diabet Med. 2010;27(8):938-948.
12. Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA. 2014;311(22):2331-2333.
13. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: ameta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28(4):950-955.
14. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26 (11):3080-3086.
15. Buysman E, Conner C, Aagren M, Bouchard J, Liu F. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes. Curr Med Res Opin. 2011;27(9):1709-1717.
16. Kennedy K. States scramble to drive down Medicaid drug costs. USA Today. August 12, 2013. http://www.usatoday.com/story/news/politics/2013/08/11/medicaid-drug-benefit/2636891/. Accessed July 7, 2015.
17. Sack K, Pear R. States consider Medicaid cuts as use grows. New York Times. February 18, 2010. http://www.nytimes.com/2010/02/19/us/politics/19medicaid.html?-r=0. Accessed July 17, 2015.
18. Cohen D. The prickly problem of access to insulin. BMJ. 2011;343:d5782.
19. Gill GV, Yudkin JS, Keen H, Beran D. The insulin dilemma in resource-limited countries: a way forward? Diabetologia. 2011;54(1):19-24.
20. Centers for Disease Control and Prevention. National diabetes fact sheet. Atlanta, GA: US Department of Health and Human Services; 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed July, 17 2015
21. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. JEMS. 1997;6(1):75-90.
22. Fleming T. Drug Topics Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Medical Economics Co; 2006.
23. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 24th ed; 2004.
24. WHO Collaborating Centre for Drug Statistics. Guidelines for ATC classification and DDD assignment, 2015. 2014. http://www.whocc.no/atc-ddd-publications/guidelines/. Accessed July 17, 2015.
25. Brown T. 100 most prescribed, best-selling branded drugs through September. 2014. http://www.medscape.com/viewarticle/834273. Accessed June 9, 2015.
26. Cunningham PJ. Medicaid cost containment and access to prescription drugs. Health Aff (Millwood). 2005;24(3):780-789.
27. Berndt ER, Aitken ML. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984Waxman-Hatch legislation. International Journal of the Economics of Business. 2011;18(2):177-201.
28. Dicken JE. Prescription Drugs: Trends in Usual and Customary (U&C) Prices for Commonly Used Drugs. Darby, PA: DIANE Publishing; 2011.
29. Kesselheim AS. Rising health care costs and life-cycle management in the pharmaceutical market. PLoS Med. 2013;10(6):e1001461.
30. Medicaid Drug Rebate Program. 2015; http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html. Accessed July 7, 2015.
31. Medicaid.gov. Cost Sharing. 2015. http://www.medicaid.gov/medicaid-chip-program-information/by-topics/cost-sharing/cost-sharing.html. Accessed May 8, 2015.
32. Centers for Medicare & Medicaid Services. Medicaid prescription reimbursement information by state: quarter ending December 2014. 2014. http://www.medicaid.gov/medicaid-chip-program-information/by-topics/benefits/prescription-drugs/state-prescription-drug-resources.html. Accessed July 17, 2015.
33. Centers for Medicare & Medicaid Services. Methodology for Calculating the National Average Drug Acquisition Cost (NADAC) for Medicaid Covered Outpatient Drugs. 2013. http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/FUL-NADAC-Downloads/NADACMethodology.pdf. Accessed July 7, 2015.
34. Bruen B, Young K. Paying for prescribed drugs in Medicaid: current policy and upcoming changes. 2014. http://kff.org/medicaid/issue-brief/paying-for-prescribed-drugs-in-medicaid-current-policy-and-upcoming-changes/. Accessed July 7, 2015.
35. European Medicines Agency. Guidance on similiar medicinal products containing recombinant human soluble insulin. 2006. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003957.pdf. Accessed December 15, 2014.
36. Guettier J-M. Tentative Approval Letter - NDA 205692. Office of Drug Evaluation II (ODE II);US Food and Drug Administration. 2014.http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/205692Orig1s000TAltr.pdf. Accessed July 17, 2015.
37. US Food and Drug Administration. Generic competition and drug prices. 2005. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129385.htm. Accessed March 31, 2015.
38. Grabowski HG, Guha R, Salgado M. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Aff (Millwood). 2014;33(6):1048-1057.